Namibia - engelsk - Namibia Medicines Regulatory Council

erongo agencies (pty) ltd - paracetamol and codeine phosphate , coffeine anhydrous and meprobamate - tablets - each tablet contain: paracetamol 320mg and codeine phosphate 8mg , coffeine anhydrous 32mg and meprobamate 150mg.

Namibia - engelsk - Namibia Medicines Regulatory Council

medpro pharmaceutica (pty) ltd - caffeine anhydrous; meprobamate; codeine phosphate ; paracetamol - tablet - each tablet contains caffeine anydrous 32 mg, meprobamate 150 mg, codeine phosphate 8 mg and paracetamol 320 mg

Namibia - engelsk - Namibia Medicines Regulatory Council

pharmacare limited - caffeine; codeine phosphate; meprobamate; paracetamol - tablet - each tablet contains caffeine 32,0 mg, codeine phosphate 8,0 mg, meprobamate 150,0 mg and paracetamol 320,0 mg

Namibia - engelsk - Namibia Medicines Regulatory Council

pharmacare limited,south africa - paracetamol, codeine phosphate, meprobamate - capsule - each capsule contains; paracetamol 320,0 mg, codeine phosphate 8,0 mg, meprobamate 150,0 mg

Namibia - engelsk - Namibia Medicines Regulatory Council

resmed pharmaceuticals c.c - paracetamol, codeine phosphate, caffeine anhydrous, meprobamate - tablets - each tablet contains paracetamol 320mg, codeine phosphate 8mg, caffeine anhydrous 32mg, meprobamate 150mg

Namibia - engelsk - Namibia Medicines Regulatory Council

sandoz (sa) (pty) ltd - paracetamol ; codeine phosphate ; caffeine; meprobamate - tablet - paracetamol 320 mg; codeine phosphate 8mg; caffeine 32mg; meprobamate 150mg

Canada - engelsk - Health Canada

merck frosst canada & cie, merck frosst canada & co. - acetylsalicylic acid; caffeine citrate; codeine phosphate; meprobamate - tablet - 350mg; 30mg; 15mg; 200mg - acetylsalicylic acid 350mg; caffeine citrate 30mg; codeine phosphate 15mg; meprobamate 200mg - salicylates

USA - engelsk - NLM (National Library of Medicine)

physician therapeutics llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - 1 indications and usage carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2)]. 4 contraindications carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. 5 warnings and precautions 5.1 sedation carisoprodol tablets may have sedative properties (in the low back pain trials, 13% to 17% of patients who received carisoprodol tablets experienced sedation compared to 6% of patients who received placebo) [see adverse reactions (6.1)] and may impair the mental and/or physical abilities required for the performance of potentially

USA - engelsk - NLM (National Library of Medicine)

stat rx usa llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 250 mg - soma is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. soma should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. soma is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of soma during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations. teratogenic effects:

USA - engelsk - NLM (National Library of Medicine)

rebel distributors corp - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 250 mg - soma is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. soma should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. soma is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of soma during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for particular congenital malformations. teratogenic effects: